Abogen Biosciences
PrivateLast Round
Grant
Feb 4, 2026
Est. Valuation
$3.1B
Total Funding Raised
$1.13B
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Abogen Biosciences is a biotechnology company that develops mRNA-based therapeutics and vaccines for infectious diseases and cancer.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Revenue Share, Government Contracts, Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Abogen Biosciences Comparables
Compare Abogen Biosciences with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Suzhou CureMed Biopharma Technology Co., Ltd | 86% | |
| Stemirna Therapeutics | 85% | |
| Innorna | 83% |
Abogen Biosciences Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Feb 4, 2026 | ||||
| Series C Extension | Nov 29, 2021 | ||||
| Series C | Aug 19, 2021 | ||||
| Series B | Apr 7, 2021 | ||||
| Series A | Oct 27, 2020 |
Key People
Founding team and executive leadership
Abogen Biosciences Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| HighLight Capital | Series C, Series B |
| Oriental Spring Capital | Series C |
| Alwin Capital | Series C |
| Jifeng Ventures | Series B |
| BioTrack Capital | Series C, Series B |
| Youshan Capital | Series C |
| Loyal Valley Capital | Series C |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 21, 2026
Monthly visitors grew 3841% MoM, reaching 2.7K.
- Apr 21, 2026
Phase I results for mRNA T-cell engager ABO2203 presented at AACR Annual Meeting.
Recent news
Latest coverage and updates
- is_developingOct 2, 2026
On Oct 2nd '26, Abogenbio said it had signed a licensing deal with Novartis to develop messenger RNA-based therapy, including the experimental drug ABO2203 and options for other RNA therapies, for up to $7.8 billion.
- licenses_technologyOct 2, 2026
On Oct 2nd '26 in China, Abogenbio announced an agreement granting Novartis Pharmaceuticals Corporation an exclusive worldwide license to ABO2203, an mRNA-encoded CD19xCD3 T-cell engager, plus exclusive options to license other programs using its RNA platform.
Abogen Biosciences Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Abogen Biosciences's valuation, stock price, and market status.
Is Abogen Biosciences a public or private company?
Abogen Biosciences is a private company.
What is the current stock price of Abogen Biosciences?
Abogen Biosciences is a private company, so its shares have no public market price. Caplight tracks Abogen Biosciences's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Abogen Biosciences worth (valuation)?
Abogen Biosciences's valuation is estimated at $3.1B based on funding round data.
Can I buy Abogen Biosciences stock?
Abogen Biosciences shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Abogen Biosciences's last funding round?
Abogen Biosciences's most recent funding round was Grant on February 4, 2026.
Who are the main investors in Abogen Biosciences?
Key investors in Abogen Biosciences include Loyal Valley Capital, SoftBank Investment Advisers, Boyu Capital, Temasek, OppenheimerFunds.
Will Abogen Biosciences IPO soon?
No public IPO plans have been announced for Abogen Biosciences.
How can I track Abogen Biosciences secondary market activity?
Caplight tracks bids, offers, and trades in Abogen Biosciences's shares on secondary markets.